---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-020539"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:01:02.765426+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Sigyn Therapeutics reports conversion of convertible debentures into 1,243,000 common shares

## Summary
- On June 2, 2023, $16,500 debenture converted into 33,000 shares at $0.50 per share.
- Also on June 2, 2023, $181,500 of other debentures converted into 1,210,000 shares at $0.15 per share.
- Outstanding shares increased from 42,981,659 to 44,224,659 as a result of these conversions.
- Remaining convertible debentures total $970,200 aggregate principal due through March 2024.

## SEC filing metadata
- accession: 0001493152-23-020539
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000149315223020539/0001493152-23-020539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000149315223020539/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-020539
- JSON: https://secwatch.observer/filing/0001493152-23-020539.json
- Plain text: https://secwatch.observer/filing/0001493152-23-020539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.